CN110092823B - Separated carp antiviral protein Pdcd6ip and antiviral activity - Google Patents

Separated carp antiviral protein Pdcd6ip and antiviral activity Download PDF

Info

Publication number
CN110092823B
CN110092823B CN201910345517.7A CN201910345517A CN110092823B CN 110092823 B CN110092823 B CN 110092823B CN 201910345517 A CN201910345517 A CN 201910345517A CN 110092823 B CN110092823 B CN 110092823B
Authority
CN
China
Prior art keywords
pdcd6ip
carp
ala
leu
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910345517.7A
Other languages
Chinese (zh)
Other versions
CN110092823A (en
Inventor
邵玲
汤茜
肖雨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Fisheries Research Institute Shanghai Fisheries Technical Extension Station
Original Assignee
Shanghai Fisheries Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fisheries Research Institute filed Critical Shanghai Fisheries Research Institute
Priority to CN201910345517.7A priority Critical patent/CN110092823B/en
Publication of CN110092823A publication Critical patent/CN110092823A/en
Application granted granted Critical
Publication of CN110092823B publication Critical patent/CN110092823B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to the technical field of freshwater fish genetic engineering, and discloses a separated carp antiviral protein Pcdd 6ip and antiviral activity, wherein the nucleotide sequence of the gene of the carp antiviral protein Pcdd 6ip is SEQ ID NO: 1, 1-2610bp, and the coded amino acid sequence is SEQ ID NO: 2, or a pharmaceutically acceptable salt thereof. Experiments show that the expression of the cloned Pdcd6ip protein can influence the proliferation of Spring Viremia of Carp Virus (SVCV), and the Pdcd6ip protein plays an important role in the process that cells resist the infection of SVCV, and has low influence on the cell activity of common cells. The gene or protein of the invention provides a new target for preparing SVCV resistant medicaments.

Description

Separated carp antiviral protein Pdcd6ip and antiviral activity
Technical Field
The invention relates to the technical field of freshwater fish genetic engineering, in particular to separated carp antiviral protein Pdcd6ip and antiviral activity.
Background
China is a big aquaculture country, but in recent years, along with the continuous development of aquaculture industry, the incidence rate of aquatic animal diseases, particularly viral diseases, shows a remarkable rising trend. This causes huge economic losses to both the aquaculture industry and import and export trade in our country, and severely restricts the health and sustainable development of the aquaculture industry in our country. Among them, Spring Viremia of Carp (SVC) is a fulminant hemorrhage caused by Spring Viremia of Carp Virus (SVCV). The disease is an acute epidemic disease which takes bleeding as a main clinical symptom and is accompanied by high infectivity, and can generate obvious symptoms in various cyprinid economic fishes and ornamental fishes such as carps, fancy carps, grass carps, silver carps, bighead carps, crucian carps and the like. SVC is often outbreak in spring at water temperature of 8-20 ℃, especially 13-15 ℃, and the outbreak of the SVC is closely related to the water temperature and the health condition of the fish body, and the more suitable the water temperature is, the worse the health condition of the fish body is, the more easily the SVC is infected. Diseased fish often gather at the water outlet, the body color is black, the eyeball is protruded, the anus is red and swollen, the abdomen is enlarged and severe ascites are caused, the breathing is slow, and the fish often loses balance and moves laterally. The disease is acute, the mortality rate can reach about 90 percent, the fishery production is seriously damaged, and destructive attack is caused, so the world animal health organization OIE classifies the disease as an important epidemic disease which needs to be declared. In 2008, the Ministry of agriculture announces 1125 that the disease is classified as an infectious disease of animals entering the country of the people's republic of China, and is also the only fish epidemic disease classified as an infectious disease so far, and is the first type of quarantine object for the port quarantine of fishes in China.
At present, the internationally prevailing effective measures for controlling the disease are to monitor the spring viremia of the carp, discover the viremia of the carp as early as possible, isolate or kill the viremia of the carp, and no medicine or method for effectively controlling the spring viremia of the carp is available. Therefore, the research for strengthening the antiviral mechanism of SVCV and the search for effective prevention and treatment methods have extremely important theoretical and practical significance.
The Programmed cell death 6 interacting protein Pdcd6ip (Programmed cell death 6-interacting protein), also known as Alix or Aip1, encoded by the Pdcd6ip gene, is a component of the Endosomal sorting transport complex III (endogenous sorting complexes required for transport III, ESCR-III), and plays an important role in regulating Programmed cell death. Studies have shown that Pdcd6ip can bind to proteins such as ALG-2, CIN85 in ESCR-III, endophilins, CHMP4B, and Tsg 101. furthermore, Pdcd6ip can bind to late domains of viruses including P (S/T) AP, YXXL, PPXY, etc., and is involved in the Endosomal transport mechanism of enveloped viruses such as human immunodeficiency virus PdHIV, equine infectious anemia virus, etc., budding and EIAV, etc., from the intracellular capsid of the vesicular cell replication mechanism 6ip, intracellular transport of viral components and budding of the whole virus are essential for normal replication of the virus. Therefore, Pdcd6ip plays an important role in regulating virus infection and replication, and the expression level thereof influence the infection and replication of the virus. Studies in EIAV showed that overexpression of Pdcd6ip inhibited its replication.
Therefore, those skilled in the art are devoted to develop an antiviral protein of carp, which has antiviral activity against spring viremia of carp, reduces SVCV infectivity, inhibits SVCV virus replication function, has low influence on cell activity of common cells, and provides a new drug target for treatment of SVCV virus infection.
Disclosure of Invention
In view of the above defects in the prior art, the technical problem to be solved by the present invention is to provide a carp antiviral protein (Pdcd6ip), which has antiviral activity against spring viremia of carp, reduces SVCV infectivity, inhibits SVCV virus replication function, does not affect the cell activity of common cells, provides a new drug target for SVCV treatment, and overcomes the defects in the prior art.
In order to achieve the aim, the invention provides an isolated carp antiviral protein Pcdd 6ip gene, wherein the nucleotide sequence of the Pcdd 6ip gene is SEQ ID NO: 1, 1-2610 bp.
The invention also provides a separated carp antiviral protein Pcdd 6ip, wherein the amino acid sequence coded by the protein Pcdd 6ip is SEQ ID NO: 2.
Further, the protein Pdcd6ip has a fragment capable of binding to the PPXY domain in the matrix protein M of Spring Viraemia of Carp Virus (SVCV).
The invention also provides a recombinant expression plasmid containing the nucleotide sequence of the Pdcd6ip gene.
The invention also provides a preparation method for preparing the recombinant expression plasmid, which is characterized by comprising the following steps of:
step one, extracting RNA of the carp, and carrying out reverse transcription on the RNA to obtain total cDNA of the carp;
designing a forward primer and a reverse primer of the Pdcd6ip gene, and amplifying by taking the total cDNA of the carp obtained in the step one as a template to obtain an amplification product;
and step three, performing molecular cloning on the amplification product obtained in the step two to obtain a recombinant expression plasmid.
Further, the second step further comprises introducing Nhe I enzyme cutting sites and EcoR I enzyme cutting sites respectively at the upstream and downstream of the carp total cDNA before amplification.
Further, the forward primer and the reverse primer are pCI-Pcdd 6ip-F and pCI-Pcdd 6ip-R respectively, wherein the DNA sequence of pCI-Pcdd 6ip-F is TTAGCTAGCCACCATGGCGACGTTTATTTCTGTC, the DNA sequence of the pCI-Pdcd6ip-R is CGGAATTCCTACTGTTGGGGGTAGTAGGGCT。
Further, the amplification product is a 2610bp DNA fragment.
The invention also provides application of the carp antiviral protein Pcdd 6ip gene in preparation of a carp spring viremia virus resistant pharmaceutical composition.
The invention also provides application of the carp antiviral protein Pcdd 6ip in preparation of a carp spring viremia virus resistant pharmaceutical composition.
Compared with the prior art, the invention has at least the following beneficial technical effects:
(1) the expression of the carp antiviral protein Pdcd6ip can influence the proliferation of Spring Viremia of Carp Virus (SVCV), inhibit the replication function of the SVCV virus and reduce the infectivity of the SVCV virus;
(2) the influence of the over-expression of the carp antiviral protein Pdcd6ip on the cell activity of common cells is extremely low;
(3) the Pdcd6ip gene and the Pdcd6ip protein provide new targets for preparing anti-spring viremia of carp virus medicines.
The conception, the specific structure and the technical effects of the present invention will be further described with reference to the accompanying drawings to fully understand the objects, the features and the effects of the present invention.
Drawings
FIG. 1 is a schematic diagram showing the amplification result of a Pdcd6ip gene fragment according to a preferred embodiment of the present invention;
FIG. 2 is a diagram showing the result of detecting the overexpression of Pdcd6ip by immunoblotting in accordance with a preferred embodiment of the present invention;
FIG. 3 is a data graph showing the effect of Pdcd6ip overexpression on cell activity measured by using CCK-8 as a cell proliferation/toxicity test reagent according to a preferred embodiment of the present invention;
FIG. 4 is a fluorescent image of the effect of Pdcd6ip protein on viral infection detected by indirect immunofluorescence according to a preferred embodiment of the present invention;
FIG. 5 is a data graph showing the effect of Pdcd6ip protein on virus proliferation detected by fluorescence quantitative PCR according to a preferred embodiment of the present invention;
FIG. 6 is a schematic diagram of the structure of an empty pCI-neo vector for use in accordance with a preferred embodiment of the present invention;
FIG. 7 is a schematic structural map of a recombinant expression plasmid pCI-Pdcd6ip prepared in accordance with a preferred embodiment of the present invention;
FIG. 8 is a schematic structural diagram of a recombinant expression plasmid pCI-flag-Pdcd6ip prepared in a preferred embodiment of the present invention.
Detailed Description
The technical contents of the preferred embodiments of the present invention will be made clear and easily understood by referring to the drawings attached to the specification. The present invention may be embodied in many different forms of embodiments and the scope of the invention is not limited to the embodiments set forth herein.
(1) RNA extraction of carp
And extracting the total RNA of the sample to be detected by adopting a classical Trizol method. Shearing Cyprinus Carpio tissue block with ophthalmologic scissors, directly placing into mortar, adding small amount of liquid nitrogen, rapidly grinding, transferring into centrifuge tube after grinding thoroughly, adding 1mL Trizol into 50-100mg tissue, mixing, standing at room temperature (15-25 deg.C) for 10min, centrifuging at 4 deg.C 12000 Xg for 5 min.
Adding 200 μ L chloroform into the supernatant, shaking, mixing, standing at room temperature for 15min, centrifuging at 4 deg.C and 12000 Xg for 15 min.
The upper aqueous phase was transferred to a new centrifuge tube, 500. mu.L of isopropanol was added, and the mixture was left on ice for 10min at 4 ℃ and 12000 Xg and centrifuged for 15 min.
The supernatant was discarded, and 1mL of 75% ethanol precooled on ice was added to wash the precipitate, which was centrifuged at 7500 Xg for 10min at 4 ℃.
The supernatant was discarded, air-dried at room temperature, and the RNA precipitate was dissolved in RNase-free water and immediately subjected to reverse transcription.
(2) Reverse transcription to obtain total cDNA of carp;
the cDNA synthesis was carried out using Invitrogen's reverse transcription kit according to the protocol, and the specific procedures were as follows:
sequentially adding 1 mu g of the extracted RNA, 1 mu L of random hexamer primer and supplementary RNase-free water into a PCR reaction tube to reach the total volume of 12 mu L; reacted at 65 ℃ for 5min, immediately placed on ice, then 4. mu.L of 5 × Reaction Buffer, 1. mu.L of RiboLock RNase Inhibitor, 2. mu.L of 10mM dNTP Mix and 1. mu.L of RevertAid M-MuLV RT were added, reacted at 25 ℃ for 5min, and then incubated at 42 ℃ for 45min to obtain the total Cyprinus Carpio cDNA.
(3) Carp pdcd6ip gene amplification
Firstly, utilizing Primer Express 5.0 software to design a forward Primer and a reverse Primer of a pdcd6ip gene, respectively introducing Nhe I enzyme cutting sites and EcoR I enzyme cutting sites at the upstream and downstream of the total carp cDNA, and carrying out PCR amplification by taking the total carp cDNA as a template, wherein the Primer sequence is as follows:
pCI-Pdcd6ip-F:TTAGCTAGCCACCATGGCGACGTTTATTTCTGTC;
pCI-Pdcd6ip-R:CGGAATTCCTACTGTTGGGGGTAGTAGGGCT。
the PCR reaction system is as follows: 50 μ L reaction system comprising ddH2O30.5. mu.L, 10 × LA Buffer II (Mg2+ plus) 5. mu.L, dNTP mix (2.5mmol/L) 8. mu.L, upstream and downstream primers (10. mu. mol/L) 2. mu.L each; LA Taq Polymerase (5U/. mu.L) 0.5. mu.L, cDNA template 2. mu.L.
The PCR reaction conditions are as follows: pre-denaturation at 95 ℃ for 5 min; denaturation at 95 ℃ for 30s, annealing at 57 ℃ for 30s, and extension at 72 ℃ for 3min for 35 cycles; extending for 10min at 72 ℃; keeping the temperature at 4 ℃.
The PCR amplification product was subjected to 1.0% agarose electrophoresis and stained with a nucleic acid stain. The voltage is 120V, electrophoresis is carried out for 30min, standard molecular weight is used as a control, 2610bp amplification product is obtained by amplification, and the amplification result is shown in figure 1.
(4) Construction of recombinant expression plasmids pCI-Pdcd6ip and pCI-flag-Pdcd6ip
According to the classical molecular cloning operation method, the PCR fragment is cut, purified and recovered by using a DNA gel recovery kit, and then the pCI-neo vector (purchased from Promega corporation, the map is shown in figure 6) and the recovered PCR fragment of the amplification product are subjected to double enzyme digestion for 3h at 37 ℃ by Nhe I and EcoR I, and the cut fragment is purified and recovered. The recovered fragments were ligated overnight at 16 ℃ with T4-DNA ligase. And transforming the ligation product into DH5 alpha escherichia coli competent cells, selecting a monoclonal for amplification culture, and carrying out PCR identification. The positive clone is further sequenced and aligned to determine the correctness of the recombinant plasmid sequence, and is named as pCI-Pdcd6ip, and all samples are sequenced by biological engineering (Shanghai) GmbH.
The construction method of the pCI-flag-Pdcd6ip plasmid is as follows: inserting a flag tag sequence in front of an initiation codon ATG in a pCI-Pdcd6ip primer, and respectively designing and synthesizing primers pCI-flag-Pdcd6 ip-F1: TTAGCTAGCCACCATGGATTACA AGGATGACGACGATAnd pCI-flag-Pdcd6 ip-F2:GGATGACGACGATAAGATGGCGACGTTTATTTCTGTC, using pCI-Pcdd 6ip plasmid with correct sequencing as a template, using pCI-flag-Pcdd 6ip-F2 and pCI-Pcdd 6ip-R primer pairs to perform first round PCR, after PCR product gel is recovered, using the first round PCR product as a template, using pCI-flag-Pcdd 6ip-F1 and pCI-Pcdd 6ip-R primer pairs to perform second round PCR, recovering PCR product gel, and the rest steps are the same as the construction method of pCI-Pcdd 6ip plasmid.
Maps of the recombinant expression plasmids pCI-Pdcd6ip and pCI-flag-Pdcd6ip are shown in FIGS. 7 and 8, respectively.
(5) Preparation of recombinant expression plasmids and empty vectors
mu.L of the well sequenced monoclonal antibody was inoculated into 3mL LB broth containing 50ug/mL ampicillin, cultured overnight on a shaker at 37 ℃ and 220rpm, and the recombinant plasmid pCI-Pdcd6ip and the empty vector pCI-neo plasmid were extracted using a plasmid extraction kit (purchased from Invitrogen) according to the following steps:
placing the overnight cultured bacterial liquid in a 1.5mL centrifuge tube, centrifuging at room temperature at 12000 Xg for 1min, discarding the supernatant, and repeating the above operations until all bacterial liquid is centrifuged;
adding 250 mu L of Resuspension Solution to the bacterial sediment for suspension precipitation;
adding 250 μ L lysine Solution, gently turning over 4-6 times, mixing to crack thallus completely until a clear Solution is formed, wherein the step is not longer than 5 min;
adding 350 μ L of Neutralization Solution, fully turning over 4-6 times, at room temperature, 12000 Xg, and centrifuging for 5 min;
the supernatant was aspirated and transferred to an adsorption column (provided in the kit), centrifuged at 12000 Xg for 1min at room temperature, and the filtrate was discarded;
washing twice with 500 μ L of Wash Solution, and discarding the filtrate; centrifuging at 12000 Xg for 1 min;
the column was transferred to a new 1.5mL centrifuge tube, 50. mu.L of Eluent was added to the center of the column membrane, and the column was allowed to stand at room temperature for 2min and centrifuged at 12000 Xg for 1 min.
(6) Transfection of EPC cells with recombinant expression plasmids and empty vectors
The specific steps are as follows (taking a 24-hole cell culture plate as an example):
determining the cell density according to the transfection purpose one day before transfection, if the cell is collected for western detection after transfection, performing transfection when the cell density reaches about 90% on the next day, and if protein positioning is observed after transfection, properly reducing the density;
transfection: a0.8. mu.g of DNA was first dissolved in 50. mu.L of Opti-MEM medium; dissolving 2 μ L Lipo 2000 in 50 μ L Opti-MEM medium, mixing, standing at room temperature for 5 min; then mixing the AB tubes, and standing at room temperature for 20 min;
during this period, the medium in the 24-well plate was changed to serum-free medium at 400. mu.L per well. If no dead cells exist in the hole, the cells can not be replaced, and the transfection efficiency is not influenced;
and adding the AB tube mixture into corresponding holes of a 24-hole plate, gently mixing uniformly at front, back, left and right, placing in an incubator, and changing into a culture medium containing 10% serum after 4-6 h.
(7) Detecting the influence of the overexpression of the recombinant plasmid pCI-Pdcd6ip on the activity of cells
The cell proliferation/toxicity detection reagent CCK-8 (purchased from Dojindo company) is used for detecting the influence of overexpression on cell activity, the CCK-8 reagent can be used for simple and accurate cell proliferation and toxicity analysis, the basic principle is that the reagent contains 2- (2-Methoxy-4-nitrophenyl) -3- (4-nitrophenyl) -5- (2, 4-disulfonic acid benzene) -2H-tetrazole monosodium salt (WST-8), the reagent can be reduced into water-soluble orange yellow formazan by dehydrogenase in cells under the action of an electron carrier 1-Methoxy PMS, the amount of generated formazan is in direct proportion to the number of cells, and the number of living cells can be indirectly determined. The method comprises the following specific steps:
one day before transfection, inoculating 100 μ L of EPC cell suspension into 96-well cell culture plate, culturing overnight, and transfecting the recombinant expression plasmid pCI-Pdcd6ip and the empty vector pCI-neo according to the method when the cell density reaches about 70% -90%;
add 10. mu.L of CCK-8 to each well at 12h, 36h and 72h post-transfection, respectively;
the plate was incubated in an incubator for 1 hour, and absorbance at 450nm was measured using a microplate reader.
The results are shown in FIG. 3, which shows that the overexpression of the recombinant plasmid pCI-Pdcd6ip does not affect the activity of the cells.
(8) Western blot immunoblotting experiment
The method comprises the following specific steps:
after transfecting the EPC cells by the recombinant expression plasmid pCI-flag-Pdcd6ip and the empty vector pCI-neo for 24 hours, discarding the supernatant, washing twice by PBS (phosphate buffer solution) for 3min each time, adding RIPA cell lysate, fully contacting the lysate with the cells by blowing with a gun, incubating on ice for 10min to lyse the cells, transferring the lysate to a 1.5mL EP tube, 12000 Xg, centrifuging for 5min, uniformly mixing 20 mu L of centrifuged supernatant with 5 mu L of 5 Xprotein loading buffer solution, boiling at 95 ℃ for 5min, and carrying out SDS-PAGE. SDS-PAGE gels were prepared using SDS-PAGE gel formulation kits (purchased from Shanghai assist in san Francisco);
cutting filter paper and PVDF membrane completely matched with gel size, and balancing in transfer buffer solution for 15 min;
after the gel electrophoresis is finished, disassembling a gel interlayer, removing concentrated gel, and balancing the gel in a proper amount of transfer buffer at room temperature for 10 min;
the transfer buffer solution is used for wetting the ink plate, the transfer interlayer is assembled, and air bubbles need to be discharged timely. Transferring protein at constant pressure for 40min at 20V;
after the membrane is transferred, taking out the membrane, putting the membrane into a hybridization box, adding 10mL of 5% PBST-BSA blocking solution for blocking, and blocking for 2h at 37 ℃ or overnight at 4 ℃;
pouring off the blocking solution, adding diluted flag tag antibody (primary antibody, purchased from Sigma and diluted in a volume ratio of 1: 1000), and slowly shaking at 37 ℃ for 2 h;
PBST was washed 3 times for 3min each, and diluted Alkaline Phosphatase (AP) -labeled goat anti-mouse IgG antibody (secondary antibody, purchased from Biyuntian corporation, diluted at a volume ratio of 1: 800) was added to the hybridization chamber and slowly shaken at 37 ℃ for 1 h;
the secondary antibody was decanted and washed 3 times for 3min in PBST. 10mL of NBT/BCIP chromogenic substrate was added and the bands developed within 5-10 min. The immunoblot results are shown in FIG. 2, indicating that Pdcd6ip was overexpressed following transfection.
(9) Indirect Immunofluorescence (IF)
Washing cells with PBS for 2 times, 3min each time, adding 300 μ L of 4% paraformaldehyde into each well, and fixing at room temperature for 30 min;
removing the fixative by aspiration, washing the cells with PBS 3 times, adding 300 μ L PBS containing 0.2% Triton X-100 per well, and permeabilizing for 15 min;
washing with PBS for 3 times, adding blocking solution containing 4% BSA, and blocking at 37 deg.C for 2 hr;
removing the blocking solution by suction, adding a primary antibody (prepared in the laboratory, rabbit anti-SVCV M protein antibody is diluted in a volume ratio of 1: 1000) diluted by the blocking solution, and incubating for 2h at 37 ℃;
removing primary antibody by suction, washing with PBS 3 times for 3min each time, adding fluorescent secondary antibody (Alexa Fluor 488-labeled donkey anti-rabbit purchased from Invitrogen corporation, diluted at a volume ratio of 1:2000), and incubating at 37 deg.C for 1 h;
absorbing secondary antibody, washing with PBS for 3 times (3 min each time), adding DAPI (1:2000) staining solution diluted with PBS for staining at room temperature for 10min, and washing with PBS for 3 times (3 min each time);
add 500. mu.L PBS to each well, place under a fluorescent inverted microscope for observation and photographing. As a result, as shown in FIG. 4, expression of Pdcd6ip inhibited infection by SVCV.
(10) Effect of overexpression of Pdcd6ip on SVCV proliferation
After transfecting the recombinant expression plasmid pCI-Pdcd6ip and the empty vector pCI-neo to EPC cells for 24h, inoculating Spring Viremia of Carp Virus (SVCV) with MOI of 0.5, and collecting supernatants of an experimental group and a control group 12h, 24h and 36h after infection respectively to perform SVCV virus titer determination. The specific operation steps are as follows:
the recombinant expression plasmid pCI-Pdcd6ip and the empty vector pCI-neo transfect EPC cells;
after 24h of transfection, the cells were washed twice with serum-free M199, and Spring Viremia of Carp Virus (SVCV) was inoculated at MOI of 0.5, adsorbed at 20 ℃ for 1 hour, and changed to M199 containing 2% FBS;
supernatants of the experimental group and the control group were collected at 12h, 24h and 36h after infection, and viral RNA was extracted using a viral RNA extraction kit (purchased from Qiagen);
reverse transcription was performed using a reverse transcription kit (purchased from Invitrogen) to synthesize cDNA;
and (3) performing virus titer determination by using a fluorescent quantitative PCR method.
The fluorescent quantitative PCR primer sequence is as follows:
a forward primer: N-TF 1: ATCAGGCCGATTATCCTTCCA, respectively;
reverse primer: N-TR 1: AGATAAGCATTCACATGCTGTAT, respectively;
sequentially adding 10 mu L of 2 XSSYBR Premix Ex Taq (TAKARA company) into a 200 mu L fluorescent PCR reaction tube, adding 0.4 mu L of each of a forward primer and a reverse primer with the concentration of 10 mu mol/L, 0.4 mu L of ROX reference dye II and 100 ng/mu L of cDNA 2 mu L of a sample to be detected, supplementing double distilled water to 20 mu L, and placing the mixture in a 7500Fast fluorescent quantitative PCR instrument for reaction under the reaction condition of 95 ℃ for 30 s; then 40 cycles of 95 ℃ for 5s, 60 ℃ for 30s and 72 ℃ for 30s are carried out, after the completion, the melting curve analysis is immediately carried out by an instrument, and finally the Tm value of the amplification product is calculated by ABI 75002.0.6 software; the virus titer of cells transfected with the empty vector pCI-neo in 24 hours is set to be 1, and as shown in FIG. 5, the over-expression of Pcdd 6ip can obviously inhibit the proliferation of the virus, which indicates that Pcdd 6ip has obvious antiviral function.
In the embodiment, the antiviral protein Pcdd 6ip gene separated from the carp by using a gene cloning technology can be combined with a PPXY structure domain existing in SVCV virus matrix protein M, and a series of tests prove that the expression of the cloned Pcdd 6ip protein gene has excellent antiviral property, reduces SVCV infectivity, inhibits SVCV virus replication function, influences the proliferation of the SVCV virus, and plays an important role in the process of resisting SVCV infection by cells. Moreover, the effect of the overexpression of Pdcd6ip on the cell activity of normal cells is extremely low. The Pdcd6ip protein and the gene thereof provide a new target for preparing an anti-SVCV medicament.
The foregoing detailed description of the preferred embodiments of the invention has been presented. It should be understood that numerous modifications and variations could be devised by those skilled in the art in light of the present teachings without departing from the inventive concepts. Therefore, the technical solutions available to those skilled in the art through logic analysis, reasoning and limited experiments based on the prior art according to the concept of the present invention should be within the scope of protection defined by the claims.
Sequence listing
<110> research institute for aquatic products in Shanghai City
<120> isolated carp antiviral protein Pdcd6ip and antiviral activity
<130> 20190417
<160> 6
<170> PatentIn version 3.5
<210> 1
<211> 2610
<212> DNA
<213> carp (Cyprinus carpio)
<400> 1
atggcgacgt ttatttctgt cccgttgaaa aagtcctcag aggtggactt agcgaaaccg 60
ttgttgaaat ttgtaactgc cacgtatcct cccggtgagg agcaggcgga gtatgtccgt 120
gccgtggaag agctcaacaa gctccgcaaa agtgctctgg ggaggccgct ggacaaacac 180
gagagctcgc tggaaatcct gcttcgatat tatgatcagc tctgtgcaat cgaacccaaa 240
tttccttttc cagagttgtg tctgacattc acttggaaag atgcttttga taaaggatca 300
ctttttggag gatcagtaaa gcttgcattg gcaagtgtgg gctatgagaa gacgtgcgtg 360
ttgtttaatg tcggtgcgct ggcgggtcag cttgcttctg agcagaatct cgacaatgac 420
gaaggactta agactgccgc caagttctac cagctggcga gtggtgcatt tgctcatata 480
aaggacactg tgctgtctgc actgaatcga gagcccacca tggacatctc ccccgagacg 540
gtgggcacgc tcagtcagat catgctcagc caggcacagg aggtcttcgt tctcaaggcc 600
actgctgata agatgaagga cgccattgtc gctaaactcg ccaaccaggc agcagattac 660
tacggcgacg cttttaagca atgtcaatac aaagagaatc tgcccaagga agcgcttcca 720
gtcctggccg ccaagcactg tatgatgcag gccaccgccg agctgcacca gtcagccttg 780
gccaatcaga agaaaaagtt cggagaggag attgctcggc tgcagcacgc cacagagctg 840
gtgaagactg cggcttccag atacgatgag tacgttaacg taaaggatct gtcagataag 900
atcagtcgtg cgctcacggc tgcaaagaag gacaacgatt tcatttacca tgatcgtgtg 960
cccggagtca aagacctgga gcacattggc aaagcatctc tggtcaaagc aactgcagtg 1020
cagattccac tcagccagaa gttcacagat ctgtttgaga agatggtgcc gatggcagta 1080
cagcagtcag tgagcgcagc caattccagg aaggctgaca cagtcaacag attgattggc 1140
agcatgagag aagcaacaaa tctctgcaat ggggtgttgg cgtctttgaa tctgccggct 1200
gcactagaag atctgtcagg agacgctgtg cctcagtcca tcctggataa gagtcgtgca 1260
gttattcagc acggaggcct gcagaacatc gaacagctga ttcgagatct ccctgaactt 1320
ctgcagagga accgtgagat cctggatgag tccttgaaga tattagatga agaggaaacg 1380
acagacaatg aactcagagc taaattcaat cagcgctgga acagaactcc ctctggagat 1440
ctgtataaat cactcagagc agagggaaat aatttttgca atatactgga caaggcagtg 1500
caggctgatc aggtgatgaa agggcgttac aatgaacatt gtgggatgat tgctttgctc 1560
tgcaagccag agaatgagat cagtgccgcc ataccgtctg ccaaccctgc caagactctg 1620
cagggcagtg aggtggtgaa cgtgctgaga gctcagctgg cacagctgga tgaggtgaag 1680
agggaacggg aagttctgga gggagaggtg aaggcggtga cctttgacct gacgacaaag 1740
ttccttaccg cactcgctca agatggtgcc attaacgagg aggccatgac caccaatgag 1800
ctggacactc gctacggctc tcacacacaa cgtgttcagc agaacttgcg ccgacaggag 1860
gaactgctgt cacagataca ggtgtctcac caggagttct cagcactgaa gcaatccaac 1920
tctgaggcta atagcagaga ggaggtgtta aagaagcttg ctgcggccca tgatagctac 1980
atcgagatca gctccaatac caaagagggc actaaattct acaatgatct gacagaaatc 2040
ctgctgaagt ttcaaaataa gtgcagcgac attgtcttcg ctcgcaaaac tgagagggat 2100
gaactgctta aggagctgca gcagagcatc gctcgtgagc cgagcgctcc ttcattcaat 2160
gtcccatcat accagtccaa cacccctgct cctgtcccag gaggcccaac ccctgcaccc 2220
aggactgtgt ttaacgcgca gcggcctcag gctaagcccc agcccccagc gagaccacca 2280
cccccgagca tcactcctca ggctgccagt gcttcagctc cagtcagttc ttcgatgggt 2340
cccggaagca ctaatcctcc acctgttgca cccactggac cctcacaggc tcaaggacca 2400
ccctatccct cttatcaagg ctacccaggg tatccaggtt accagatgcc aatggcctat 2460
aacccctatg catacgggca gtttaatatg ccctacatgc cctatcaagc ccaggggcag 2520
gctgggtacc ctggagcccc tcctacacag cagccctacc cttaccccca acaaccccca 2580
cagcagcagc cctactaccc ccaacagtag 2610
<210> 2
<211> 869
<212> PRT
<213> carp (Cyprinus carpio)
<400> 2
Met Ala Thr Phe Ile Ser Val Pro Leu Lys Lys Ser Ser Glu Val Asp
1 5 10 15
Leu Ala Lys Pro Leu Leu Lys Phe Val Thr Ala Thr Tyr Pro Pro Gly
20 25 30
Glu Glu Gln Ala Glu Tyr Val Arg Ala Val Glu Glu Leu Asn Lys Leu
35 40 45
Arg Lys Ser Ala Leu Gly Arg Pro Leu Asp Lys His Glu Ser Ser Leu
50 55 60
Glu Ile Leu Leu Arg Tyr Tyr Asp Gln Leu Cys Ala Ile Glu Pro Lys
65 70 75 80
Phe Pro Phe Pro Glu Leu Cys Leu Thr Phe Thr Trp Lys Asp Ala Phe
85 90 95
Asp Lys Gly Ser Leu Phe Gly Gly Ser Val Lys Leu Ala Leu Ala Ser
100 105 110
Val Gly Tyr Glu Lys Thr Cys Val Leu Phe Asn Val Gly Ala Leu Ala
115 120 125
Gly Gln Leu Ala Ser Glu Gln Asn Leu Asp Asn Asp Glu Gly Leu Lys
130 135 140
Thr Ala Ala Lys Phe Tyr Gln Leu Ala Ser Gly Ala Phe Ala His Ile
145 150 155 160
Lys Asp Thr Val Leu Ser Ala Leu Asn Arg Glu Pro Thr Met Asp Ile
165 170 175
Ser Pro Glu Thr Val Gly Thr Leu Ser Gln Ile Met Leu Ser Gln Ala
180 185 190
Gln Glu Val Phe Val Leu Lys Ala Thr Ala Asp Lys Met Lys Asp Ala
195 200 205
Ile Val Ala Lys Leu Ala Asn Gln Ala Ala Asp Tyr Tyr Gly Asp Ala
210 215 220
Phe Lys Gln Cys Gln Tyr Lys Glu Asn Leu Pro Lys Glu Ala Leu Pro
225 230 235 240
Val Leu Ala Ala Lys His Cys Met Met Gln Ala Thr Ala Glu Leu His
245 250 255
Gln Ser Ala Leu Ala Asn Gln Lys Lys Lys Phe Gly Glu Glu Ile Ala
260 265 270
Arg Leu Gln His Ala Thr Glu Leu Val Lys Thr Ala Ala Ser Arg Tyr
275 280 285
Asp Glu Tyr Val Asn Val Lys Asp Leu Ser Asp Lys Ile Ser Arg Ala
290 295 300
Leu Thr Ala Ala Lys Lys Asp Asn Asp Phe Ile Tyr His Asp Arg Val
305 310 315 320
Pro Gly Val Lys Asp Leu Glu His Ile Gly Lys Ala Ser Leu Val Lys
325 330 335
Ala Thr Ala Val Gln Ile Pro Leu Ser Gln Lys Phe Thr Asp Leu Phe
340 345 350
Glu Lys Met Val Pro Met Ala Val Gln Gln Ser Val Ser Ala Ala Asn
355 360 365
Ser Arg Lys Ala Asp Thr Val Asn Arg Leu Ile Gly Ser Met Arg Glu
370 375 380
Ala Thr Asn Leu Cys Asn Gly Val Leu Ala Ser Leu Asn Leu Pro Ala
385 390 395 400
Ala Leu Glu Asp Leu Ser Gly Asp Ala Val Pro Gln Ser Ile Leu Asp
405 410 415
Lys Ser Arg Ala Val Ile Gln His Gly Gly Leu Gln Asn Ile Glu Gln
420 425 430
Leu Ile Arg Asp Leu Pro Glu Leu Leu Gln Arg Asn Arg Glu Ile Leu
435 440 445
Asp Glu Ser Leu Lys Ile Leu Asp Glu Glu Glu Thr Thr Asp Asn Glu
450 455 460
Leu Arg Ala Lys Phe Asn Gln Arg Trp Asn Arg Thr Pro Ser Gly Asp
465 470 475 480
Leu Tyr Lys Ser Leu Arg Ala Glu Gly Asn Asn Phe Cys Asn Ile Leu
485 490 495
Asp Lys Ala Val Gln Ala Asp Gln Val Met Lys Gly Arg Tyr Asn Glu
500 505 510
His Cys Gly Met Ile Ala Leu Leu Cys Lys Pro Glu Asn Glu Ile Ser
515 520 525
Ala Ala Ile Pro Ser Ala Asn Pro Ala Lys Thr Leu Gln Gly Ser Glu
530 535 540
Val Val Asn Val Leu Arg Ala Gln Leu Ala Gln Leu Asp Glu Val Lys
545 550 555 560
Arg Glu Arg Glu Val Leu Glu Gly Glu Val Lys Ala Val Thr Phe Asp
565 570 575
Leu Thr Thr Lys Phe Leu Thr Ala Leu Ala Gln Asp Gly Ala Ile Asn
580 585 590
Glu Glu Ala Met Thr Thr Asn Glu Leu Asp Thr Arg Tyr Gly Ser His
595 600 605
Thr Gln Arg Val Gln Gln Asn Leu Arg Arg Gln Glu Glu Leu Leu Ser
610 615 620
Gln Ile Gln Val Ser His Gln Glu Phe Ser Ala Leu Lys Gln Ser Asn
625 630 635 640
Ser Glu Ala Asn Ser Arg Glu Glu Val Leu Lys Lys Leu Ala Ala Ala
645 650 655
His Asp Ser Tyr Ile Glu Ile Ser Ser Asn Thr Lys Glu Gly Thr Lys
660 665 670
Phe Tyr Asn Asp Leu Thr Glu Ile Leu Leu Lys Phe Gln Asn Lys Cys
675 680 685
Ser Asp Ile Val Phe Ala Arg Lys Thr Glu Arg Asp Glu Leu Leu Lys
690 695 700
Glu Leu Gln Gln Ser Ile Ala Arg Glu Pro Ser Ala Pro Ser Phe Asn
705 710 715 720
Val Pro Ser Tyr Gln Ser Asn Thr Pro Ala Pro Val Pro Gly Gly Pro
725 730 735
Thr Pro Ala Pro Arg Thr Val Phe Asn Ala Gln Arg Pro Gln Ala Lys
740 745 750
Pro Gln Pro Pro Ala Arg Pro Pro Pro Pro Ser Ile Thr Pro Gln Ala
755 760 765
Ala Ser Ala Ser Ala Pro Val Ser Ser Ser Met Gly Pro Gly Ser Thr
770 775 780
Asn Pro Pro Pro Val Ala Pro Thr Gly Pro Ser Gln Ala Gln Gly Pro
785 790 795 800
Pro Tyr Pro Ser Tyr Gln Gly Tyr Pro Gly Tyr Pro Gly Tyr Gln Met
805 810 815
Pro Met Ala Tyr Asn Pro Tyr Ala Tyr Gly Gln Phe Asn Met Pro Tyr
820 825 830
Met Pro Tyr Gln Ala Gln Gly Gln Ala Gly Tyr Pro Gly Ala Pro Pro
835 840 845
Thr Gln Gln Pro Tyr Pro Tyr Pro Gln Gln Pro Pro Gln Gln Gln Pro
850 855 860
Tyr Tyr Pro Gln Gln
865
<210> 3
<211> 34
<212> DNA
<213> Artificial sequence (Artificial sequence)
<400> 3
ttagctagcc accatggcga cgtttatttc tgtc 34
<210> 4
<211> 31
<212> DNA
<213> Artificial sequence (Artificial sequence)
<400> 4
cggaattcct actgttgggg gtagtagggc t 31
<210> 5
<211> 37
<212> DNA
<213> Artificial sequence (Artificial sequence)
<400> 5
ttagctagcc accatggatt acaaggatga cgacgat 37
<210> 6
<211> 37
<212> DNA
<213> Artificial sequence (Artificial sequence)
<400> 6
ggatgacgac gataagatgg cgacgtttat ttctgtc 37

Claims (9)

1. A separated carp antiviral protein Pdcd6ip gene, wherein the nucleotide sequence of the Pdcd6ip gene is SEQ ID NO: 1, 1-2610 bp.
2. An isolated antiviral protein Pcdd 6ip for carp, wherein the amino acid sequence of the protein Pcdd 6ip is SEQ ID NO: 2, or a pharmaceutically acceptable salt thereof.
3. A recombinant expression plasmid comprising the nucleotide sequence of the Pdcd6ip gene of claim 1.
4. A method of making the recombinant expression plasmid of claim 3, comprising the steps of:
step one, extracting RNA of a carp, and performing reverse transcription on the RNA to obtain total cDNA of the carp;
designing a forward primer and a reverse primer of the Pdcd6ip gene, and amplifying by taking the total cDNA of the carp obtained in the step one as a template to obtain an amplification product;
and step three, performing molecular cloning on the amplification product obtained in the step two to obtain a recombinant expression plasmid.
5. The method for preparing the recombinant expression plasmid according to claim 4, wherein the second step further comprises introducing Nhe I and EcoR I cleavage sites into the upstream and downstream of the total Cyprinus carpio cDNA, respectively, before amplification.
6. The method for preparing the recombinant expression plasmid of claim 4, wherein the forward primer and the reverse primer are pCI-Pdcd6ip-F and pCI-Pdcd6ip-R, respectively, and the DNA sequence of the pCI-Pdcd6ip-F is TTAGCTAGCCACCATGGCGACGTTTATTTCTGTC, the DNA sequence of the pCI-Pdcd6ip-R is CGGAATTCCTACTGTTGGGGGTAGTAGGGCT。
7. The method of claim 4, wherein the amplification product is a 2610bp DNA fragment.
8. An application of the antiviral protein Pdcd6ip gene of carp as claimed in claim 1 in preparation of a pharmaceutical composition for resisting spring viraemia of carp virus.
9. An application of the antiviral protein Pdcd6ip of carp in claim 2 in preparation of a pharmaceutical composition for resisting spring viraemia of carp virus.
CN201910345517.7A 2019-04-26 2019-04-26 Separated carp antiviral protein Pdcd6ip and antiviral activity Active CN110092823B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910345517.7A CN110092823B (en) 2019-04-26 2019-04-26 Separated carp antiviral protein Pdcd6ip and antiviral activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910345517.7A CN110092823B (en) 2019-04-26 2019-04-26 Separated carp antiviral protein Pdcd6ip and antiviral activity

Publications (2)

Publication Number Publication Date
CN110092823A CN110092823A (en) 2019-08-06
CN110092823B true CN110092823B (en) 2022-05-20

Family

ID=67446084

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910345517.7A Active CN110092823B (en) 2019-04-26 2019-04-26 Separated carp antiviral protein Pdcd6ip and antiviral activity

Country Status (1)

Country Link
CN (1) CN110092823B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113698469B (en) * 2021-06-21 2023-04-21 深圳大学 Method and reagent for capturing host cell membrane-associated protein of SVCV

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104611343A (en) * 2015-01-20 2015-05-13 华中农业大学 Isolated antiviral natural immune protein TRIM32 (tripartite motif 32) for carps and antiviral activity
CN109439638A (en) * 2018-10-19 2019-03-08 华中农业大学 A kind of isolated fish antivirus protein gene CMPK2 and its antiviral activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104611343A (en) * 2015-01-20 2015-05-13 华中农业大学 Isolated antiviral natural immune protein TRIM32 (tripartite motif 32) for carps and antiviral activity
CN109439638A (en) * 2018-10-19 2019-03-08 华中农业大学 A kind of isolated fish antivirus protein gene CMPK2 and its antiviral activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Genomic evidence of homologous recombination in spring viremia ofcarp virus: A negatively single stranded RNA virus;Yu Xiao等;《Virus Research》;20140620;第189卷;271-279 *
鲤春病毒血症病毒核蛋白、磷蛋白与基质蛋白的表达、抗体制备及免疫原性比较;张海强等;《水产学报》;20171231;第41卷(第12期);1919-1927 *

Also Published As

Publication number Publication date
CN110092823A (en) 2019-08-06

Similar Documents

Publication Publication Date Title
Ciminale et al. Expression and characterization of proteins produced by mRNAs spliced into the X region of the human T-cell leukemia/lymphotropic virus type II
CN113498417B (en) Polypeptide, preparation method and application thereof
CN109640946A (en) The negative-feedback regu- lation of HIV-1 is carried out by gene editing strategy
CN102863516B (en) Production of cell-penetrating peptide hPP10 (human Pancreatic Polypeptide) and transfection method for mediated plasmid DNA (Deoxyribose Nucleic Acid) of hPP10
CN113512096B (en) Weever rhabdovirus recombinant G2 protein and application thereof
CN111620952A (en) Novel coronavirus vaccine based on chimeric virus-like particles
JP2021531727A (en) Recombinant vector for antigen production for the diagnosis of African swine fever and its use
Fujinaga et al. Extracellular Nef protein regulates productive HIV-1 infection from latency.
US8685652B2 (en) Targets and compounds for therapeutic intervention of HIV infection
CN110092823B (en) Separated carp antiviral protein Pdcd6ip and antiviral activity
CN110064044B (en) Enterovirus 71 inhibitor and application thereof
CN112587660B (en) Application of Seneca valley virus 3D protein in preparation of immune response inducer or adjuvant
KR102332725B1 (en) Pentamer-based recombinant protein vaccine platform and expressing system there of
CN110295173B (en) Isolated carp antiviral protein Rhbdd3 and antiviral activity thereof
Chen et al. Development and evaluation of nucleoprotein-based rapid detection test for Siniperca chuatsi rhabdovirus
NO329619B1 (en) Conditionally replicating viral vectors, method of preparation, compositions and their use
CN107988239B (en) Recombinant gene of Zika virus and preparation method and application thereof
CN109439638B (en) Separated fish antiviral protein gene CMPK2 and antiviral activity thereof
CN110372780B (en) Antitumor polypeptide and application thereof in antitumor field
CN109836490A (en) It is a kind of to target the T cell receptor of MAGE-A3, T cell receptor gene modification T cell and its preparation method and application
WO2013127300A1 (en) Polypeptide for use in inhibiting hiv, pharmaceutical composition of the polypeptide, and use thereof
CN114907490B (en) Potent bifunctional HIV entry inhibitor and application thereof
Echarri et al. Human immunodeficiency virus (HIV) Nef is an RNA binding protein in cell-free systems
US20050256067A1 (en) Method of preparing a treatment product, treatment product and a plasmid construct
CN113121667B (en) Cell membrane pore-forming protein LjGSDM and expression and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: 200433 No. 265, Jiamusi Road, Shanghai, Yangpu District

Patentee after: SHANGHAI FISHERIES Research Institute SHANGHAI FISHERIES TECHNICAL EXTENSION STATION

Address before: 200433 No. 265, Jiamusi Road, Shanghai, Yangpu District

Patentee before: SHANGHAI FISHERIES Research Institute

CP01 Change in the name or title of a patent holder